On this page
How do you prepare a pediatric exclusivity determination request?
Reconcile the complete issued Written Request and amendments with the reports actually submitted, their locations and the applicable timing. Explain how each term was addressed and disclose departures or missing material. Ask FDA for the determination without equating report delivery, favorable study results, pediatric approval or a future exclusivity expiry date with the agency’s decision.
Before you begin
Preparation of a pediatric-exclusivity determination request for a product and applicant with an FDA Written Request.
What you will prepare: A terms-to-evidence reconciliation and transparent request for agency determination.
Start with the issued request, not the planned studies
Collect the original Written Request, every effective amendment, the applicant/product identities, report-submission plan and receipt records. A meeting agreement, an iPSP or a postmarketing commitment is not automatically a Written Request.
Build a matrix with each operative term, supporting report or analysis, exact location, relevant dates and any departure. Include populations, endpoints, formulation, study conditions and timing when specified. The strongest request lets FDA see how the entire package responds; it does not rely on the author declaring “all requirements met” without a map.
Write a narrow, verifiable request
Identify the determination sought and the Written Request being answered. Describe the submitted package, where the full reports and required supporting material reside, and which term each item addresses. Explain discrepancies candidly, including incomplete work, changed methods or timing. Have the responsible specialists assess whether the facts support the requested determination.
Study responsiveness, product approval, pediatric labeling and the legal attachment of an exclusivity period are separate questions. Do not state that a positive study or a filed report automatically earns six additional months. Product-specific patent/exclusivity and biologic statutory analysis belongs with the regulatory/legal owner; the May 2023 draft should not be used as an automatic expiry-date calculator.
Worked review: the report is complete but the package is not
Fictional editorial exercise: the main pediatric study report is final, but a formulation study specified in the latest amendment has not been included. The draft request cites only the original Written Request.
Update the matrix to the operative amendment and identify the missing study. Do not hide the gap in a general statement that the clinical objectives were achieved. If an FDA letter actually removed the study, locate and reference it. Without that letter, the disposition is unresolved. Preserve the agency's eventual determination separately from the sponsor's request.
Make the response to every operative term inspectable
Use the issued Written Request as the row structure for the reconciliation. The May 2023 draft recommends an annotated request identifying how and where each term has been addressed. The working table below implements that idea; it is an editorial aid, not a substitute for the complete reports or the actual agency request.
| Operative term | Evidence and location to identify | Question to resolve |
|---|---|---|
| Population and age groups | Study population, eligibility and disposition in the report | Were all specified groups addressed, or is there an explained departure? |
| Study objective and endpoints | Protocol, amendments, analysis plan and relevant results | Does the evidence address the requested question? |
| Formulation and administration | Product identity and actual study-use records | Was the requested formulation used, or was a change formally addressed? |
| Study conditions and analyses | Methods, conduct, analyses and supporting material | Are required elements present and scientifically interpretable? |
| Completion and submission timing | Actual dates, submission references and operative request deadline | Does the package meet the applicable timing? |
| Amendments | Issued letter and exactly which terms changed | Is the author relying on an issued amendment or only a proposed one? |
Give each row a specific disposition: addressed with a location; departure requiring explanation; or evidence not yet available. Do not use “complete” to mean merely that a PDF was uploaded. A favorable endpoint result does not establish that the study population, formulation and timing match the request.
Completeness exercise: the clinical study report is final, but the request also calls for a formulation assessment that is missing. The team points to an email proposing removal of that assessment. Locate the actual FDA amendment. If it was not issued, the proposal does not remove the term; preserve the gap and resolve the package against the operative request. If an amendment did remove it, cite that precise disposition instead of submitting unnecessary replacement material.
In the cover narrative, identify the request and amendments, the determination sought, the report package and any prior relevant submissions. The draft guidance recommends a clear determination-request header, copies of the request and amendments, a study summary, the annotated request and proposed labeling reflecting the results. Treat that as draft preparation guidance and reconcile the actual application route and filing requirements.
Keep four decisions separate: whether the reports respond to the request, whether the product or pediatric use is approved, what labeling is appropriate, and how any exclusivity period legally attaches. FDA’s FAQ explains that pediatric approval is not the same decision as the initial exclusivity determination. This guide does not calculate product-specific patent or exclusivity dates, and its initial-determination discussion should not be generalized to a second period of exclusivity.
The public determination list can illustrate the relationship between requests and amendments, but it identifies particular sponsors and is not your operative record. Return to the PPSR and amendment guide when a term still needs resolution, and keep the PREA plan synchronized without treating it as the Written Request.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a positive pediatric study result automatically qualify for exclusivity?
No. FDA must assess the submitted studies against the issued Written Request, including its terms and timing. A positive result does not cure a missing study, an unaddressed population or an unsupported change. Build the determination request from the complete operative record rather than the most favorable efficacy finding.
Must pediatric labeling already be approved before the initial exclusivity determination?
FDA’s FAQ distinguishes the exclusivity determination from approval and identifies compliance with the Written Request as pivotal. That does not remove the need to address appropriate labeling or other submission obligations. Keep the initial determination separate from product approval and from the different conditions relevant to any second exclusivity period.
Can a meeting agreement or postmarketing commitment replace the Written Request?
No. FDA’s FAQ expressly distinguishes prior correspondence, meeting agreements and phase 4 commitments from a Written Request. Obtain the issued request and amendments for the actual applicant and product. Without that record, the writer cannot establish which terms the exclusivity submission is intended to satisfy.
Can another sponsor’s public determination establish eligibility for this application?
No. FDA’s public list identifies particular drugs, sponsors and determination records, and notes that only applications held by the identified sponsor received the exclusivity. Use it as context, not as the operative decision for a different applicant. Verify this application’s own request, evidence and agency determination.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
FDA resource
FDA pediatric exclusivity questions and answers ↗Live FDA resource, Q1–4 checked September 22, 2026. Historical office names and references to withdrawn guidance are not used as current instructions.
Draft guidance
Pediatric Drug Development: Regulatory Considerations ↗May 2023, Revision 1; DRAFT, not for implementation. Sections III–IV are contextual recommendations, not final guidance.
FDA resource
FDA pediatric exclusivity determinations and Written Requests ↗Live FDA list checked September 22, 2026. Historical examples are not the operative request for a different applicant.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.9.3. A heading identifies placement, not mandatory applicability.